Month: May 2024

SAN DIEGO, May 15, 2024 (GLOBE NEWSWIRE) — Cidara Therapeutics, Inc. (Nasdaq: CDTX) (the Company), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) immunotherapies designed to save lives and improve the standard of care for patients facing serious diseases, today reported financial results for the first quarter ended March 31, 2024, and provided an update on its corporate activities and product pipeline. “Our reacquisition of our CD388 program, which we have developed to date in collaboration with Janssen Pharmaceuticals, Inc., a Johnson & Johnson Company, (Janssen) as a once-per-flu season universal preventative of influenza A and B, along with the divestiture of the rezafungin program to our former partner Mundipharma, enables us to focus all of our development efforts...

Fortress‘ late-stage pipeline continues to advance and may generate up to three regulatory approvals on NDAs and BLAs in the next 12 months and potentially a fourth BLA filing as early as 2025 FDA accepted New Drug Application filing for DFD-29 to treat inflammatory lesions and erythema of rosacea in adults; PDUFA goal date of November 4, 2024 MIAMI, May 15, 2024 (GLOBE NEWSWIRE) — Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress”), an innovative biopharmaceutical company focused on acquiring and advancing assets to enhance long-term value for shareholders through product revenue, equity holdings and dividend and royalty revenue, today announced financial results and recent corporate highlights for the first quarter ended March 31, 2024. Lindsay A. Rosenwald, M.D., Fortress’ Chairman, President and Chief Executive Officer, said,...

Preliminary safety and efficacy with sustained objective responses observed in patients with lymphoma treated with MT-601 in Phase 1 APOLLO study Study participant with Non-Hodgkin’s Lymphoma who relapsed within 90 days of anti-CD19 CAR T cell therapy remains in complete response nine months after MT-601 treatment Company received approval from United States Adopted Name (USAN) council and International Nonproprietary Names (INN) expert committee for “neldaleucel” as nonproprietary name for MT-601 HOUSTON, May 15, 2024 (GLOBE NEWSWIRE) — Marker Therapeutics, Inc. (Nasdaq: MRKR), a clinical-stage immuno-oncology company focusing on developing next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumors, today reported corporate updates and financial results for the first quarter ended...

Announced private placement of up to $19.25M with healthcare funds and insiders Received $3M award recommendation from the Department of Defense to support Plus’ clinical brain cancer program Acquired synergistic leptomeningeal metastases diagnostic portfolio and announced related positive top-line FORESEE clinical trial data Management to Host Conference Call May 15, 2024 at 5:00 p.m. ET AUSTIN, Texas, May 15, 2024 (GLOBE NEWSWIRE) — Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system cancers, today announced financial results for the first quarter ended March 31, 2024, and provided an overview of recent and upcoming business highlights. Q1 2024 AND RECENT HIGHLIGHTS AND MILESTONE ACHIEVEMENTS...

LOS ANGELES, May 15, 2024 (GLOBE NEWSWIRE) — Nova LifeStyle, Inc. (NASDAQ: NVFY) (“Nova LifeStyle” or the “Company”) today announced financial results for the first quarter ended March 31, 2024. Tawny Lam, Chairperson and Chief Executive Officer of Nova LifeStyle, stated, “It is with great pleasure that we announce financial and operating results that showed increases in revenues, sales volume and higher gross profit margins. We continue to collaborate with our customers to ensure we provide furniture that meets their needs with respect to design, functionality and trends, while also working with manufacturers and suppliers on a consistent basis resulting in product availability and maintaining satisfactory inventory levels.” Key Financial Highlights:Net sales for the three months ended March 31, 2024 were $2.38 million, an increase...

Revenue of $66.0 million for Q1 2024 Net loss of $6.3 million for Q1 2024 Gross profit (exclusive of depreciation and amortization) of $18.6 million for Q1 2024 Media margin of $22.1 million for Q1 2024 Adjusted EBITDA of $0.7 million for Q1 2024 Adjusted net loss of $4.2 million for Q1 2024    NEW YORK, May 15, 2024 (GLOBE NEWSWIRE) — Fluent, Inc. (NASDAQ: FLNT), a leading data-driven performance marketing company, today reported financial results for the first quarter ended March 31, 2024. Don Patrick, Fluent’s Chief Executive Officer, commented, “For the quarter, we reported improved gross margins over last year with positive adjusted EBITDA as we continued to deliver both leading and emerging brands a broader suite of customer acquisition and partner monetization solutions. Our new syndicated performance marketplaces...

SAN DIEGO, May 15, 2024 (GLOBE NEWSWIRE) —  KULR Technology Group, Inc. (NYSE American: KULR) (the “Company” or “KULR”), a global leader in sustainable energy management, today reported results for the first quarter ended March 31, 2024. First Quarter 2024 Financial Results Revenues: In the first quarter that ended March 31, 2024, revenue was flat at $1.75 million compared to $1.76 million reported in the same period last year. Contract Services revenue increased 769%, with revenue of approximately $1.13 million versus approximately $131 thousand in the same quarter last year. Cash and Accounts Receivable: As of March 31, 2024, the Company had cash and accounts receivable combined of $1.78 million. Gross Margins: Gross margin was 29% in the quarter ending March 31, 2024, compared to 37% in the same period...

353% Revenue Growth with improvement in Adjusted EBITDA SARASOTA, Fla., May 15, 2024 (GLOBE NEWSWIRE) — INVO Bioscience, Inc. (Nasdaq: INVO) (“INVO” or the “Company”), a healthcare services fertility company focused on expanding access to advanced treatment worldwide through the establishment and acquisition of fertility clinics, and with the intravaginal culture (“IVC”) procedure enabled by its INVOcell® medical device, today announced financial results for the first quarter of 2024 and provided a business update. Q1 2024 Financial Highlights (all metrics compared to Q1 2023 unless otherwise noted)Revenue was $1,576,286, an increase of 353% compared to $348,025. Clinic revenue increased 417% to $1,537,199, compared to $297,381. All reported clinic revenue is derived from the Company’s...

LONDON, May 15, 2024 (GLOBE NEWSWIRE) — Financial HighlightsOn May 14, 2024, the Board of Navigator Holdings Ltd. (NYSE: NVGS) declared a cash dividend of $0.05 per share for the quarter ended March 31, 2024, (the “Dividend”) under the Company’s Return of Capital policy. The Dividend will be payable on June 25, 2024, to all shareholders of record as of the close of business U.S. E.D.T. on June 4, 2024.Also as part of the Company’s Return of Capital policy for the quarter ended March 31, 2024, the Company expects to repurchase approximately $2.0 million of common stock between May 16, 2024, and June 30, 2024, subject to operating needs, market conditions, and other circumstances, such that the Dividend and share repurchases together equal 25% of net income for the quarter ended March 31, 2024.The Company repurchased...